CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase 3, Multicenter, Open-Label, Long-Term Trial to Evaluate the Safety and Efficacy of Efgartigimod (ARGX-113) PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT04812925
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-09-24T00:04:15.858931+00:00
Published At: 2026-09-23T00:00:00+00:00
Record Updated At: 2026-09-23
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Primary Immune Thrombocytopenia"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2026-09-23"
protocolSection.identificationModule.nctId: "NCT04812925"
protocolSection.identificationModule.officialTitle: "A Phase 3, Multicenter, Open-Label, Long-Term Trial to Evaluate the Safety and Efficacy of Efgartigimod (ARGX-113) PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia"
protocolSection.statusModule.overallStatus: "ACTIVE_NOT_RECRUITING"
protocolSection.designModule.phases: ["PHASE3"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.